CAR T cell therapy in multiple myeloma, where are we now and where are we heading for?

被引:3
|
作者
Fischer, Luise [1 ]
Grieb, Nora [1 ,2 ]
Platzbecker, Uwe [1 ]
Vucinic, Vladan [1 ]
Merz, Maximilian [1 ]
机构
[1] Univ Hosp Leipzig, Dept Hematol Cellular Therapy Hemostaseol & Infect, Leipzig, Germany
[2] Univ Leipzig, Innovat Ctr Comp Assisted Surg ICCAS, Leipzig, Germany
关键词
CAR T cells; ciltacabtagene autoleucel; CRS; ICANS; idecabtagene vicleucel; multiple myeloma; refractory; relapsed; PROTEIN-COUPLED RECEPTOR; SINGLE-ARM; TRANSPLANT; BORTEZOMIB; PHASE-1; GPRC5D; LOCUS;
D O I
10.1111/ejh.14051
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The introduction of chimeric antigen receptor (CAR) T cells revolutionized treatment of relapsed and refractory multiple myeloma (RRMM) in recent years. Currently, two CAR T cell products-idecabtagene vicleucel and ciltacabtagene autoleucel-are approved in the United States and the European Union to treat patients with three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody. Moreover, seminal phase III trials of both agents in earlier lines of therapy have been published recently. Despite unprecedented rates of deep and lasting remissions in RRMM, there are still areas of uncertainty regarding the optimal use and distribution of CAR T cells in multiple myeloma. In the current review, we discuss the available data on approved CAR T cell products as well as unmet clinical needs and ongoing developments to optimize usage of this promising treatment modality in multiple myeloma.
引用
收藏
页码:19 / 27
页数:9
相关论文
共 50 条
  • [41] WHERE WE STAND AND WHERE WE ARE HEADING
    Laufer, Miguel
    [J]. INTERCIENCIA, 2016, 41 (04) : 226 - 226
  • [42] Pharmacogenetics - where are we and where are we heading?
    Kola, I
    [J]. PHARMACOGENOMICS, 2005, 6 (08) : 793 - 795
  • [43] Artificial intelligence in radiology: friend or foe? Where are we now and where are we heading?
    Pakdemirli, Emre
    [J]. ACTA RADIOLOGICA OPEN, 2019, 8 (02):
  • [44] Photodynamic therapy in urology: What can we do now and where are we heading?
    Bozzini, G.
    Colin, P.
    Betrouni, N.
    Nevoux, P.
    Ouzzane, A.
    Puech, P.
    Villers, A.
    Mordon, S.
    [J]. PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY, 2012, 9 (03) : 261 - 273
  • [45] Introduction to Special Issue on Outcome Measures for IDD: Where We Have Been, Where We Are Now, and Where We Are Heading
    Kelleher, Bridgette L.
    Wheeler, Anne C.
    [J]. AJIDD-AMERICAN JOURNAL ON INTELLECTUAL AND DEVELOPMENTAL DISABILITIES, 2020, 125 (06): : 413 - 417
  • [46] HAEMATOLOGICAL CANCER Where are we now with the treatment of multiple myeloma?
    Morgan, Gareth J.
    Rasche, Leo
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2017, 14 (08) : 461 - 462
  • [47] DRUG-THERAPY FOR HYPERTENSION - WHERE WE ARE, AND WHERE WE MIGHT BE HEADING
    WILSON, TW
    QUEST, DW
    [J]. CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE, 1994, 85 : S48 - S50
  • [48] Dental occlusion, body posture and temporomandibular disorders: where we are now and where we are heading for
    Manfredini, D.
    Castroflorio, T.
    Perinetti, G.
    Guarda-Nardini, L.
    [J]. JOURNAL OF ORAL REHABILITATION, 2012, 39 (06) : 463 - 471
  • [49] Drivers and barriers of circular economy business models: Where we are now, and where we are heading
    Hina, Maryam
    Chauhan, Chetna
    Kaur, Puneet
    Kraus, Sascha
    Dhir, Amandeep
    [J]. JOURNAL OF CLEANER PRODUCTION, 2022, 333
  • [50] Quality assessment in surgery: where do we stand now and where should we be heading?
    Weyers, S.
    Van Calenbergh, S.
    Van Nieuwenhove, Y.
    Mestdagh, G.
    Coppens, M.
    Bosteels, J.
    [J]. GYNECOLOGICAL SURGERY, 2014, 11 (02) : 89 - 95